Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We studied the prognostic value of clinical and laboratory variables, measured before blood cell transplantation, in predicting complete response among patients undergoing autologous blood cell transplantation for relapsed or primary refractory myeloma. Sixty-seven patients who underwent transplantation for relapsed or primary refractory myeloma were studied. The overall response rate was 90%, and the complete response rate was 33%. Low β2-microglobulin (≤ 2.7 mg/l) was associated with a significantly better complete response rate compared with high levels (54 vs 19%, P = 0.002). Similarly, the complete response rate was 39% when the bone marrow plasma cell percentage was low (< 40%) and 21% with greater involvement (P = 0.04). Complete response rate was 50% when β2-microglobulin and bone marrow plasma cell percentage were low, 36% if either was high, and 12% when both were high (P = 0.01). Median survival measured from initial diagnosis of myeloma was 51 months. Overall survival after transplantation was better among responders who achieved complete response than those who did not: median survival, 24 vs 11 months, P = 0.04 (log-rank) and 0.009 (Gehan-Wilcoxon). Attainment of a complete response independently predicted better survival in a multivariate analysis. β2-Microglobulin and bone marrow plasma cell percentage predict complete responders among patients undergoing transplantation for myeloma.

Original languageEnglish (US)
Pages (from-to)1261-1266
Number of pages6
JournalBone Marrow Transplantation
Volume23
Issue number12
StatePublished - Jun 2 1999

Fingerprint

Cell Transplantation
Plasma Cells
Bone Marrow Cells
Blood Cells
Survival
Transplantation
Multivariate Analysis

Keywords

  • β-microglobulin
  • Complete response
  • Multiple myeloma
  • Prognostic factors
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{cedcae4ecafa4b10b87723473241b125,
title = "Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma",
abstract = "We studied the prognostic value of clinical and laboratory variables, measured before blood cell transplantation, in predicting complete response among patients undergoing autologous blood cell transplantation for relapsed or primary refractory myeloma. Sixty-seven patients who underwent transplantation for relapsed or primary refractory myeloma were studied. The overall response rate was 90{\%}, and the complete response rate was 33{\%}. Low β2-microglobulin (≤ 2.7 mg/l) was associated with a significantly better complete response rate compared with high levels (54 vs 19{\%}, P = 0.002). Similarly, the complete response rate was 39{\%} when the bone marrow plasma cell percentage was low (< 40{\%}) and 21{\%} with greater involvement (P = 0.04). Complete response rate was 50{\%} when β2-microglobulin and bone marrow plasma cell percentage were low, 36{\%} if either was high, and 12{\%} when both were high (P = 0.01). Median survival measured from initial diagnosis of myeloma was 51 months. Overall survival after transplantation was better among responders who achieved complete response than those who did not: median survival, 24 vs 11 months, P = 0.04 (log-rank) and 0.009 (Gehan-Wilcoxon). Attainment of a complete response independently predicted better survival in a multivariate analysis. β2-Microglobulin and bone marrow plasma cell percentage predict complete responders among patients undergoing transplantation for myeloma.",
keywords = "β-microglobulin, Complete response, Multiple myeloma, Prognostic factors, Transplantation",
author = "Rajkumar, {S Vincent} and Rafael Fonseca and Martha Lacy and Witzig, {Thomas Elmer} and Lust, {J. A.} and Greipp, {P. R.} and Therneau, {Terry M} and Kyle, {R. A.} and Litzow, {Mark R} and Morie Gertz",
year = "1999",
month = "6",
day = "2",
language = "English (US)",
volume = "23",
pages = "1261--1266",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma

AU - Rajkumar, S Vincent

AU - Fonseca, Rafael

AU - Lacy, Martha

AU - Witzig, Thomas Elmer

AU - Lust, J. A.

AU - Greipp, P. R.

AU - Therneau, Terry M

AU - Kyle, R. A.

AU - Litzow, Mark R

AU - Gertz, Morie

PY - 1999/6/2

Y1 - 1999/6/2

N2 - We studied the prognostic value of clinical and laboratory variables, measured before blood cell transplantation, in predicting complete response among patients undergoing autologous blood cell transplantation for relapsed or primary refractory myeloma. Sixty-seven patients who underwent transplantation for relapsed or primary refractory myeloma were studied. The overall response rate was 90%, and the complete response rate was 33%. Low β2-microglobulin (≤ 2.7 mg/l) was associated with a significantly better complete response rate compared with high levels (54 vs 19%, P = 0.002). Similarly, the complete response rate was 39% when the bone marrow plasma cell percentage was low (< 40%) and 21% with greater involvement (P = 0.04). Complete response rate was 50% when β2-microglobulin and bone marrow plasma cell percentage were low, 36% if either was high, and 12% when both were high (P = 0.01). Median survival measured from initial diagnosis of myeloma was 51 months. Overall survival after transplantation was better among responders who achieved complete response than those who did not: median survival, 24 vs 11 months, P = 0.04 (log-rank) and 0.009 (Gehan-Wilcoxon). Attainment of a complete response independently predicted better survival in a multivariate analysis. β2-Microglobulin and bone marrow plasma cell percentage predict complete responders among patients undergoing transplantation for myeloma.

AB - We studied the prognostic value of clinical and laboratory variables, measured before blood cell transplantation, in predicting complete response among patients undergoing autologous blood cell transplantation for relapsed or primary refractory myeloma. Sixty-seven patients who underwent transplantation for relapsed or primary refractory myeloma were studied. The overall response rate was 90%, and the complete response rate was 33%. Low β2-microglobulin (≤ 2.7 mg/l) was associated with a significantly better complete response rate compared with high levels (54 vs 19%, P = 0.002). Similarly, the complete response rate was 39% when the bone marrow plasma cell percentage was low (< 40%) and 21% with greater involvement (P = 0.04). Complete response rate was 50% when β2-microglobulin and bone marrow plasma cell percentage were low, 36% if either was high, and 12% when both were high (P = 0.01). Median survival measured from initial diagnosis of myeloma was 51 months. Overall survival after transplantation was better among responders who achieved complete response than those who did not: median survival, 24 vs 11 months, P = 0.04 (log-rank) and 0.009 (Gehan-Wilcoxon). Attainment of a complete response independently predicted better survival in a multivariate analysis. β2-Microglobulin and bone marrow plasma cell percentage predict complete responders among patients undergoing transplantation for myeloma.

KW - β-microglobulin

KW - Complete response

KW - Multiple myeloma

KW - Prognostic factors

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0033516045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033516045&partnerID=8YFLogxK

M3 - Article

C2 - 10414913

AN - SCOPUS:0033516045

VL - 23

SP - 1261

EP - 1266

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -